Akoya Biosciences - שווי פירמה כולל AKYA

Akoya Biosciences (AKYA) relies on an autonomous product development cycle, making its business resilient to global crises and a reliable asset. The company's US-based facilities produce advanced tissue analysis systems for pharmaceutical laboratories. Current price action on GURU.Markets, where the Enterprise Value is , confirms the company's status as a technological leader in high-precision biomedical mapping.

Enterprise value combines market capitalization with net debt, determining the actual cost of a full business buyout while accounting for its liquidity. By analyzing the consolidated enterprise value, an investor assesses the effectiveness of the "razor-and-blade" model of Akoya Biosciences (AKYA), where the high margins on consumables must justify the current market valuation of assets and the company's debt load.